Oppenheim, Joost J., M.D.
individual record
Senior Investigator
Positions:
- Senior Investigator, Cancer and Inflammation Program
Research Areas:
Research & Experimental Medicine,
Engineering,
Science & Technology - Other Topics,
Oncology,
Biochemistry & Molecular Biology,
Materials Science,
Biophysics,
Pharmacology & Pharmacy,
Infectious Diseases,
Cell Biology,
Chemistry,
Hematology,
Life Sciences & Biomedicine - Other Topics,
Immunology
Research Areas:
overview
Dr. Oppenheim obtained his M.D. degree from the Columbia College of Physicians and Surgeons, New York, trained as a clinical associate at the National Cancer Institute (NCI), Bethesda, Maryland, and was a postdoctoral fellow at the University of Birmingham, England, in immunology. He returned to the National Institute of Dental Research and subsequently headed the Section of Cellular Immunology there and, since 1983, has been head of the Laboratory of Molecular Immunoregulation, NCI-Frederick.
selected publications
Academic Articles457
- (2019). Cryptotanshinone has curative dual anti-proliferative and immunotherapeutic effects on mouse Lewis lung carcinoma. CANCER IMMUNOLOGY IMMUNOTHERAPY. 68(7), 1059-1071.
- (2019). Inhibition of murine hepatoma tumor growth by cryptotanshinone involves TLR7-dependent activation of macrophages and induction of adaptive antitumor immune defenses. CANCER IMMUNOLOGY IMMUNOTHERAPY. 68(7), 1073-1085.
- (2019). Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines. JOURNAL OF IMMUNOLOGY. 202(1), 5-9.
- (2018). Blockade of TNFR2 signaling enhances the immunotherapeutic effect of CpG ODN in a mouse model of colon cancer. Science Signaling. 11(511),
- (2018). Combined treatment with HMGN1 and anti-CD4 depleting antibody reverses T cell exhaustion and exerts robust anti-tumor effects in mice. Journal for ImmunoTherapy of Cancer. 7,
- (2018). HMGN1 and R848 Synergistically Activate Dendritic Cells Using Multiple Signaling Pathways. Frontiers in Immunology. 9,
- (2018). High-mobility group nucleosome binding domain 1 (HMGN1) functions as a Th1-polarizing alarmin. SEMINARS IN IMMUNOLOGY. 38(C), 49-53.
- (2017). A Role for Neuronal Alpha-Synuclein in Gastrointestinal Immunity. Journal of Innate Immunity. 9(5), 456-463.
- (2017). Development of a Curative Therapeutic Vaccine (TheraVac) for the Treatment of Large Established Tumors. Scientific Reports. 7,
- (2017). Targeting TNFR2, an immune checkpoint stimulator and oncoprotein, is a promising treatment for cancer. Science Signaling. 10(462),
- (2016). IL-23 induced in keratinocytes by endogenous TLR4 ligands polarizes dendritic cells to drive IL-22 responses to skin immunization. JOURNAL OF EXPERIMENTAL MEDICINE. 213(10), 2147-2166.
- (2016). Paradoxical effects of targeting TNF signalling in the treatment of autoimmunity. Nature Reviews Rheumatology. 12(11), 625-626.
- (2016). Suppressive activity of human regulatory T cells is maintained in the presence of TNF. NATURE MEDICINE. 22(1), 16-+.
- (2016). TNFR2 expression by CD4 effector T cells is required to induce full-fledged experimental colitis. Scientific Reports. 6,
- (2016). TNFR2 expression by CD4 effector T cells is required to induce full-fledged experimental colitis (vol 6, 32834, 2016). Scientific Reports. 6,
- (2015). Characterization of MT-2 cells as a human regulatory T cell-like cell line. Cellular & Molecular Immunology. 12(6), 780-782.
- (2015). Enhanced immunostimulatory effects of DNA-encapsulated peptide hydrogels. BIOMATERIALS. 53, 545-553.
Research Areas:
Research & Experimental Medicine,
Engineering,
Science & Technology - Other Topics,
Oncology,
Biochemistry & Molecular Biology,
Materials Science,
Biophysics,
Pharmacology & Pharmacy,
Infectious Diseases,
Cell Biology,
Chemistry,
Hematology,
Life Sciences & Biomedicine - Other Topics,
Immunology
Research Areas: